Safety of Oral Echinacea Preparations: Systematic Review and Meta-Analysis in the Context of Therapeutic Benefit
Planta Medica · 12.11.2026
DOI: 10.1055/a-2992-1199 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Planta Medica, online erschienen am 12.11.2026. Verfasst von Mercedes Ogal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Integrative Medizin Innerschweiz AG, Pediatric Clinic, Switzerland, Brunnen. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recent literature has assessed the potential of Echinacea products to reduce respiratory tract infections (RTIs) and antibiotic use but has not comprehensively evaluated safety within a risk–benefit framework. Our systematic review and meta-analysis reviewed relevant databases for adverse events (AEs) in clinical trials comparing oral Echinacea (all species and preparations) with placebo, active, or no-treatment groups. AEs were classified by System Organ Class (SOC) and compared with individual case safety reports (ICRs) from EudraVigilance (EVDAS). Across 48 clinical studies (N = 10,115), 2,396 AEs were reported. AE occurrence was lower in Echinacea groups compared with any control (22.7% vs. 24.8%, p = 0.014) and to placebo control only (29.1% vs. 32.3%; p = 0.005). In therapeutic settings, after excluding pressed juice formulations, Echinacea significantly reduced AEs by up to 21.1% (19.8% vs. 25.1%; p < 0.0001). Preventive studies in healthy participants showed comparable AE rates between Echinacea and control groups (21.3% vs. 22.3%; p = 0.411). Serious AEs (SAEs) accounted for 0.09% and 0.08% of events for Echinacea and any control, respectively; no fatal SAEs were reported. Spontaneous EVDAS reports mostly concerned gastrointestinal (17.7%), general (13.1%), and nervous system disorders (10.3%, e.g., headache), whereas skin and subcutaneous tissue events (16.1%) were less prominent in clinical trials, which predominantly investigated high-quality pharmaceutical extracts. Principally, oral Echinacea products demonstrate a high level of safety, with preparation-dependent qualitative differences. Pharmaceutical-grade ethanolic extracts showed further reductions in AEs versus control, possibly reflecting clinical efficacy and supporting positive risk–benefit evaluation for RTI management and antibiotic stewardship.
Autor:innen und Institutionen
- Integrative Medizin Innerschweiz AG, Pediatric Clinic, Switzerland, Brunnen.
- University of Southampton, Primary Care and Population Science, United Kingdom of Great Britain and Northern Ireland, Southampton.
- University of Graz, Institute of Pharmaceutical Sciences, Austria, Graz.
- Imperial College London, National Heart and Lung Institute, England, United Kingdom of Great Britain and Northern Ireland, London.
- University of Ljubljana, Faculty of Pharmacy, Slovenia, Ljubljana.
- "Sodobna fitoterapija" phytotherapy school, Slovenia, Divača.
ORCID-Profile: Mercedes Ogal, Rudolf Bauer
Zitieren
APA
Ogal, M., Willcox, M., Bauer, R., Johnston, S. L., Kreft, S., Booker, A., Schapowal, A., Roux, D., Gancitano, G., & Stange, R. (2026). Safety of Oral Echinacea Preparations: Systematic Review and Meta-Analysis in the Context of Therapeutic Benefit. Planta Medica. https://doi.org/10.1055/a-2992-1199
Vancouver
Ogal M, Willcox M, Bauer R, Johnston SL, Kreft S, Booker A, et al. Safety of Oral Echinacea Preparations: Systematic Review and Meta-Analysis in the Context of Therapeutic Benefit. Planta Medica. 2026. doi:10.1055/a-2992-1199
BibTeX
@article{Ogal2026,
author = {Ogal, Mercedes and Willcox, Merlin and Bauer, Rudolf and Johnston, Sebastian L and Kreft, Samo and Booker, Anthony and Schapowal, Andreas and Roux, Danielle and Gancitano, Giuseppe and Stange, Rainer},
title = {Safety of Oral Echinacea Preparations: Systematic Review and Meta-Analysis in the Context of Therapeutic Benefit},
journal = {Planta Medica},
year = {2026},
doi = {10.1055/a-2992-1199}
}
EUVIMED